Our use of periodic regimen of the ER-β agonist pretreatment could avoid serious side effects, such as breast and uterine cancers, since ER-β-selective agonist does not stimulate the proliferation of breast or endometrial tissues. Here, ESR2 is linked to uterine cancer.